［4］Rinehart K L. Antumor compounds from tunicates. Med Res Rev, 2000, 20(1):1-27
[4]
［5］Schwarlsmann G. Marine organisms and other novel natural sources of new cancer drugs. Ann Onc, 2000, 11(Suppl 3):235-243
[5]
［6］Shu Y Z. Recent nature products based drug development: a pharmaceutical industry perspective. J Nat Prod, 1998, 61(8): 1 053-1 061
[6]
［7］Delaoge S, Yovine A, Taamma A, et al. Ecteinascidin-743:a marine derived compound in advanced, pretreated sarcoma patients preliminary evidence of activity. J Clin Onc, 2001,19(5): 1 248-1 255
[7]
［8］Toske S G, Jensen P R, Kauffman C A, et al. Aspergillamides A and B: modified cytotoxic tripeptides produced by a marine Fungus of the Genus Aspergillus. Tetrahedron,1998, 54(44): 13 459-13 466
[8]
［9］Sponga F, Cavaletti L, Lazzarini A, et al. Biodiversity and Potentials of marine-derived microorganisms. J Biotechnology, 1999, 70(1-3): 65-69
[9]
［10］Fenical W. New phanaceuticals from marine organisms.Trends Marine Biotechnology, 1997, 15(9): 339-341
[10]
［11］Cragg G M, Newman D J, Weise R B. Coral reefs, forests,and thermal vents: the worldwide exploration of natural for novel antitumor agents. Semi Onc, 1997, 24(2):156-163
[11]
［12］Munro M H G, Blunt J W, Dumdei E J, et al. The discovery and development of marine compounds with pharmaceutical potential. J Biotechnology, 1999, 70(1-3):15-25
[12]
［13］Schwartsmann G, Da-Rocha A B, Berlinck R G S. Marine organisms as a source of new anticancer agents. Lancet Onc,2001, 2(4): 221-225
[13]
［14］Ter H E, Kowalski R J, Hamel E, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubuls more potential than taxol, Biochemistry, 1996, 35(1): 243-250
[14]
［15］Poncet J .The dolastatins, a family of promising antineoplastic agents. Current Pharmaceu Design, 1999, 5(3): 139-162
[15]
［16］Wang L G, Liu X M, Kreis W, et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis:a review. Cancer Chemother Pharmacol, 1999, 44(5):355-361
[16]
［17］Jordan A, Hadfield J A, Lawrence N J, et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev, 1998,18(4):259-296
[17]
［18］Dassonneville L, Wattez N, Baldeyrou B, et al. Inhibition of topoisomerase Ⅱ by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem Phar macol, 2000, 60(4):527-537
[18]
［19］Kanegawa K, Harada H, Myouga H, et al. Telomerase inhibiting activity in vitro from natural resouces, marine algae extracts. Cytotechnology, 2000, 33(1-3): 221-227
[19]
［20］Frey M R, Leontieva O, Watters D J, et al. Stimulation of protein kinase C-dependent and -independent signaling pathways by bistratene A intestinal epithelial cells. Biochem Pharmacol, 2001, 61(9): 1 093-1 100
[20]
［21］HoodKA, WestLM, Northcote PT, etal. Induction of apoptosis by the marine sponge (Mycale) metabolites,mycalamide A and pateamine. Apoptosis, 2001, 6(3):207-219
[21]
［22］Deslandes E, Pondaven P, Auperin T, et al. Preliminary study of the in vitro antiproliferative effect of a hydroethanolic extract from the subtropical seaweed Turbinaria omate (Turner J. Agardh) on a human non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). J Appl Phycol, 2000, 12(3-5): 257-262
[22]
［23］Wang H, Rajagopal S, Reynolds S, et al. Differen tiation-prormoting effect of 1-O(2 methoxy) hexadecyl glycerol in human colon cancer cells. J Cel Physiol, 1999, 178(2):173-178
[23]
［24］Wender P A, Hinkle K W, Koehler M F, et al. The rational design of potential chemotherapeutic agents: synthesis of bryostain analogues. Med Res Rev, 1999, 19(5): 388-407
[24]
［25］Li Q F, Ouyang G L, Li C Y, et al. Effects of tachyplesin on the morphology and ultrastructure of the human gastric carcinoma cell line BGC-823. World J Gastroentero, 2000,6(5): 676-680
[25]
［26］Chen Y X, Xu X M, Hong S G, et al. RGD-tachyplesin inhibits tumor growth. Cancer Res, 2001, 61(6): 2 434-2 438
